T Cell-Derived IL-17A Induces Vascular Dysfunction Via Perivascular Fibrosis Formation and Dysregulation of NO/cGMP Signaling
Overview
Endocrinology
Authors
Affiliations
Aims: The neutrophil recruiting cytokine Interleukin-17A (IL-17A) is a key component in vascular dysfunction and arterial hypertension. Moreover, IL-17A has a central role for the vascular infiltration of myeloid cells into the arterial wall in Angiotensin II-induced vascular inflammation. The intention of our study was to analyze the impact of T cell-derived IL-17A on hypertension, vascular function, and inflammation.
Methods And Results: Chronic IL-17A overexpression in T cells (CD4-IL-17A mice) resulted in elevated reactive oxygen species in the peripheral blood and a significant vascular dysfunction compared to control mice. The vascular dysfunction seen in the CD4-IL-17A mice was only accompanied by a modest and nonsignificant accumulation of inflammatory cells within the vessel wall. Therefore, infiltrating myeloid cells did not serve as an explanation of the vascular dysfunction seen in a chronic IL-17A-driven mouse model. In addition to vascular dysfunction, CD4-IL-17A mice displayed vascular fibrosis with highly proliferative fibroblasts. This fibroblast proliferation was induced by exposure to IL-17A as confirmed by experiments with primary murine fibroblastic cells. We also found that the NO/cGMP pathway was downregulated in the vasculature of the CD4-IL-17A mice, while levels of protein tyrosine kinase 2 (PYK2), an oxidative stress-triggered process associated with T cell activation, were upregulated in the perivascular fat tissue (PVAT).
Conclusions: Our data demonstrate that T cell-derived IL-17A elicits vascular dysfunction by mediating proliferation of fibroblasts and subsequent vascular fibrosis associated with PYK2 upregulation.
Review of mechanisms and frontier applications in IL-17A-induced hypertension.
Li R, Guo L, Liang B, Sun W, Hai F Open Med (Wars). 2025; 20(1):20251159.
PMID: 40028265 PMC: 11868716. DOI: 10.1515/med-2025-1159.
Role of MTH1 in oxidative stress and therapeutic targeting of cancer.
Taiyab A, Ashraf A, Sulaimani M, Rathi A, Shamsi A, Hassan M Redox Biol. 2024; 77:103394.
PMID: 39418911 PMC: 11532495. DOI: 10.1016/j.redox.2024.103394.
Bibliometric analysis of T-cells immunity in pulmonary hypertension from 1992 to 2022.
Chen X, Yan Z, Pan Q, Zhang C, Chen Y, Liang X Immun Inflamm Dis. 2024; 12(7):e1280.
PMID: 38967362 PMC: 11225084. DOI: 10.1002/iid3.1280.
Couture C, Brien M, Rechtzigel J, Ling S, Ledezma-Soto C, Duran Bishop G Front Immunol. 2024; 15:1380629.
PMID: 38745664 PMC: 11091301. DOI: 10.3389/fimmu.2024.1380629.
An emerging view on vascular fibrosis molecular mediators and relevant disorders: from bench to bed.
Hua R, Gao H, He C, Xin S, Wang B, Zhang S Front Cardiovasc Med. 2024; 10:1273502.
PMID: 38179503 PMC: 10764515. DOI: 10.3389/fcvm.2023.1273502.